Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Clearside Biomedical (CLSD) Weakness a Buying Opportunity - Wedbush
December 9, 2016 12:29 PM ESTWedbush analyst Liana Moussatos reiterated an Outperform rating and $28 price target on Clearside Biomedical (NASDAQ: CLSD), saying weakness is unwarranted and represents a buying opportunity.
"Investor sentiment declined for drug stocks following recent unexpected political comments about decreasing drug pricing," Moussatos... More
